The EPS beat is misleading, revenue declined 10% YoY and adjusted EBITDA loss widened. The reaffirmed guidance of 0-5% full-year revenue decline suggests no near-term catalyst for recovery. Monitor Q2 2026 for signs of stabilization; the $115M credit facility provides a liquidity buffer but does not address the fundamental demand headwinds.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $2.01entry
- T+1 · 6mo ago −3.48%α −3.71% · $1.94
- T+5 · 6mo ago +37.81%α +36.35% · $2.77
- T+20 · 5mo ago +74.63%α +74.60% · $3.51
- T+60 · 4mo ago +135.82%α +130.98% · $4.74
Price Chart
How similar events traded
Executive Summary
Treace Medical Concepts reported Q1 2026 revenue of $47.2M (down 10% YoY) and a GAAP net loss of $(0.28)/share, beating consensus EPS estimates of $(0.31) by 51.6%. The company reaffirmed full-year 2026 revenue guidance of $202M-$212M (decline of 5%-0% YoY) and expects continued cash burn reduction, but the top-line decline and widening adjusted EBITDA loss signal ongoing operational headwinds.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $47.2M, down 10% YoY from $52.6M
- GAAP net loss $(0.28)/share vs consensus $(0.31), beat on EPS but driven by cost cuts, not revenue growth
- Adjusted EBITDA loss widened to $(5.5)M from $(3.8)M YoY
- Full-year 2026 revenue guidance reaffirmed at $202M-$212M (decline of 5%-0% YoY)
- Cash & marketable securities $51.9M, up $3.5M from Dec 2025; credit facility provides additional $115M
- Operating cash flow improved to +$7.2M vs +$4.2M in Q1 2025
- Gross margin slightly compressed to 79.3% from 79.7% YoY
- Total operating expenses down $2.9M YoY to $54.6M, driven by sales & marketing and R&D cuts
Financial Impact
Revenue decline of $5.4M YoY (10%) with net loss widening by $2.0M; full-year guidance implies continued top-line contraction
Risk Factors
- Continued revenue decline driven by product mix shift and competitive pressure in bunion surgery market
- Widening adjusted EBITDA loss signals deteriorating operating leverage
- Macroeconomic headwinds and soft consumer sentiment may further depress elective bunion surgery volumes
- Patent litigation costs ($2.3M in Q1) add to cash burn without guarantee of favorable outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291003 |
Track record
11 reports on TMCI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
- Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
- Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
- Nov 6, 202611d ago 8-K Neutral 4/10 Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
- Aug 7, 202614w ago 8-K Mixed 6/10 Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
- Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
- May 8, 202627w ago Press Release Bearish 7/10 Viewing Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
- Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
- Apr 9, 202631w ago 8-K Mixed 6/10 Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers